The results of our study demonstrate that treatment with AD inhibits ox-LDL-stimulated VSMC proliferation, which is strongly associated with the inhibition of the ERK1/2 and miR-17∼92a activation. The gene discussed is MAPK3; the disease is Alzheimer disease.